Downloads: 2 | Views: 81 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Comparative Studies | Ophthalmology | India | Volume 12 Issue 1, January 2023
Comparison of Intravitreal Dexamethasone Implant with Aflibercept for Treatment of Macular Edema (Me) in Branch Retinal Vein Occlusion (BRVO)
Dr. Mayank Jhanwar | Dr. Rajat Chaudhary | Dr. Saurabh Kushwaha | Dr Anchal Tripathi
Abstract: Objectives: To compare Intravitreal Aflibercept with Dexamethasone implant for the treatment of Macular Edema in BRVO. Methods: 70 patients with freshly diagnosed BRVO having ME were included. Patients were randomised into two equal groups with 35 patients in each group. One group was given 2 mg of Intravitreal Aflibercept and the other group was given 0.7 mg Dexamethasone Implant. Initial treatment followed by pro re nata (PRN) regimen of IV Aflibercept. Patients in group 2 were treated with only one dose of 0.7 mg Dexamethasone implant. Best-corrected visual acuity (BCVA), central macular thickness (CMT), Intraocular pressure (IOP) measurements were noted at baseline. Post procedure follow up was done at First and Seventh day, followed by check up at 1st, 2nd, 3rd and 4th months. Results: The mean CMT in Group 1 reduced from 398.17?63.99 microns to 274.83?68.24 microns whereas the mean CMT in Group 2 reduced from 381.43?51.87 microns to 349.09?82.23 microns. The difference in Macular thickness at the end of 4 months was statistically significant between the two groups (p <0.001). Eight people developed increase in IOP in group 2, with a mean IOP increase of 3.4 mmmHg. The raised IOP was managed with topical therapy. Three patients developed visually insignificant cataract in group 2. Conclusion: Reduction in CMT was statistically significantin patients treated with Aflibercept as compared to Dexamethasone Implant. The group treated with Intravitreal Aflibercept showed better safety profife as compared to the Dexamethasone group.
Keywords: Aflibercept, branch retinal vein occlusion, dexamethasone, macular edema
Edition: Volume 12 Issue 1, January 2023,
Pages: 1034 - 1038